Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells

P De Isabella, G Capranico, M Binaschi, S Tinelli and F Zunino

Division of Experimental Oncology B, Istituto Nazionale Tumori, Milan, Italy.

A multidrug-resistant variant of the P388 leukemia cell line exhibits multiple biochemical changes, including reduced drug accumulation and markedly reduced DNA strand breakage induced by anthracyclines. To investigate whether the reduced formation of drug-induced DNA breaks was due to alteration of DNA topoisomerase II activity, nuclear extracts and partially purified enzymes from the sensitive line and the resistant subline were compared. DNA topoisomerase II activity in 0.35 M NaCl nuclear extracts from sensitive cells was approximately 1.7 times higher than that found in extracts from resistant cells, as determined by ability to unknot P4 phage DNA. In addition, it was found that teniposide-stimulated topoisomerase II DNA cleavage activity of nuclear extract from resistant cells was at least 10-fold lower than that from sensitive cells. This differential sensitivity paralleled a similar drug response of nuclei, as determined by the alkaline elution method. However, partially purified DNA topoisomerase II showed similar drug sensitivity in both cell lines. This finding suggests the presence of a modulating factor, which may be lost during purification. These results, indicating a reduction of both catalytic activity and DNA cleavage activity of DNA topoisomerase II in P388 multidrug-resistant cells, emphasize the importance of DNa topoisomerase function in the resistance mechanism. Thus, the concomitant involvement of multiple mechanisms could explain the high degree of resistance of these cells.

Volume 37, Issue 1, pp. 11-16, 01/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				F. Guano, P. Pourquier, S. Tinelli, M. Binaschi, M. Bigioni, F. Animati, S. Manzini, F. Zunino, G. Kohlhagen, Y. Pommier, et al. Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines Mol. Pharmacol., July 1, 1999; 56(1): 77 - 84. [Abstract] [Full Text]

				C. Sissi, L. Bolgan, S. Moro, G. Zagotto, C. Bailly, E. Menta, G. Capranico, and M. Palumbo DNA-Binding Preferences of Bisantrene Analogues: Relevance to the Sequence Specificity of Drug-Mediated Topoisomerase II Poisoning Mol. Pharmacol., December 1, 1998; 54(6): 1036 - 1045. [Abstract] [Full Text]

				G. Capranico, F. Guano, S. Moro, G. Zagotto, C. Sissi, B. Gatto, F. Zunino, E. Menta, and M. Palumbo Mapping Drug Interactions at the Covalent Topoisomerase II-DNA Complex by Bisantrene/Amsacrine Congeners J. Biol. Chem., May 22, 1998; 273(21): 12732 - 12739. [Abstract] [Full Text] [PDF]

				S. Patel, A. U. Sprung, B. A. Keller, V. J. Heaton, and L. M. Fisher Identification of Yeast DNA Topoisomerase II Mutants Resistant to the Antitumor Drug Doxorubicin: Implications for the Mechanisms of Doxorubicin Action and Cytotoxicity Mol. Pharmacol., October 1, 1997; 52(4): 658 - 666. [Abstract] [Full Text]